ProQR Therapeutics NV

PRQR

1.500USD

+0.040+2.74%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

ProQR Therapeutics NV's Score

Industry at a Glance

Industry Ranking

137 / 392

Overall Ranking

281 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

ProQR Therapeutics NV Highlights

StrengthsRisks

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 348.01% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 18.01M.

Overvalued

The company’s latest PE is -4.27, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.27M shares, decreasing 10.09% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 750.00K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

9.000

Target Price

+516.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of ProQR Therapeutics NV is 6.23, ranking 278 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.52M, representing a year-over-year decrease of 31.49%, while its net profit experienced a year-over-year decrease of 27.01%.

Score

Industry at a Glance

Previous score

6.23

Change

0



Financials

7.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.78

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of ProQR Therapeutics NV is 6.22, ranking 311 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.27, which is -53.78% below the recent high of -1.97 and -298.90% above the recent low of -17.03.

Score

Industry at a Glance

Previous score

6.22

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 137/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of ProQR Therapeutics NV is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 14.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of ProQR Therapeutics NV is 6.65, ranking 204 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.94 and the support level at 1.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.51

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of ProQR Therapeutics NV is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.22%, representing a quarter-over-quarter decrease of 3.38%. The largest institutional shareholder is Steven Cohen, holding a total of 750.00K shares, representing 0.71% of shares outstanding, with 0.13% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Eli Lilly and Company

16.90M

+26.35%

Van Herk Investments

14.33M

+17.44%

Adage Capital Management, L.P.

6.25M

-5.28%

Privium Fund Management BV

5.00M

+0.01%

Affinity Asset Advisors LLC

3.60M

+2.87%

abrdn Inc.

2.30M

+24.24%

Morgan Stanley & Co. LLC

2.89M

-5.61%

Sio Capital Management, LLC

2.08M

--

Kynam Capital Management LP

1.65M

--

Dafna Capital Management, LLC

1.57M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ProQR Therapeutics NV is 2.53, ranking 223 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

ProQR Therapeutics NV

PRQR

6.11 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment